📊 COEPW Key Takeaways
Investment Thesis
Coeptis Therapeutics is a pre-revenue biotech company with severe operational losses and negative cash burn that is unsustainable at current run rates. The company generated only $1.4M in revenue while burning $8.6M in operating cash flow, resulting in a -631% free cash flow margin with minimal runway based on $5.7M cash reserves. Despite strong balance sheet liquidity metrics, the company exhibits classic characteristics of a failing biotech venture with deteriorating fundamentals and no clear path to profitability.
COEPW Strengths
- Strong current ratio of 4.16x indicates short-term liquidity to meet immediate obligations
- Minimal debt burden with 0.01x debt-to-equity ratio providing financial flexibility
- High gross margin of 86.7% suggests strong unit economics if revenue scales, typical of biotech
- 9 Form 4 filings in last 90 days indicate insider engagement and activity
COEPW Risks
- Extreme cash burn of $8.6M annually against only $1.4M revenue is unsustainable; ~8 months of cash runway remaining
- Operating margin of -956.9% and net margin of -874.3% indicate massive losses with no near-term profitability path
- Minimal revenue generation suggests failed commercialization, late-stage development issues, or loss of market traction
- Negative ROE of -87.9% and ROA of -73.8% demonstrate value destruction for shareholders
- Pre-revenue biotech status with no clear pipeline success or upcoming catalyst visible in fundamentals
Key Metrics to Watch
- Operating cash flow trend and months of cash runway remaining
- Revenue growth trajectory and pipeline advancement milestones
- Quarterly cash burn rate changes and capital efficiency improvements
- Clinical trial progress and FDA approval status for key programs
- Working capital management and potential dilutive financing needs
COEPW Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.16x current ratio provides a solid financial cushion.
COEPW Profitability Ratios
COEPW vs Finance Sector
How Coeptis Therapeutics Holdings, Inc. compares to Finance sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
COEPW Balance Sheet & Liquidity
COEPW 5-Year Financial Trend
5-Year Trend Summary: Coeptis Therapeutics Holdings, Inc.'s revenue has grown significantly by 1,717% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.56 indicates the company is currently unprofitable.
COEPW Growth Metrics (YoY)
COEPW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$1.8M | $-0.05 |
| Q2 2025 | N/A | -$3.0M | $-0.08 |
| Q1 2025 | N/A | -$3.0M | $-0.08 |
| Q3 2024 | N/A | -$1.8M | $-0.05 |
| Q2 2024 | N/A | -$3.0M | $-0.08 |
| Q1 2024 | N/A | -$3.0M | $-0.08 |
| Q3 2023 | N/A | -$3.1M | $-0.23 |
| Q2 2023 | N/A | -$3.1M | $-0.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
COEPW Capital Allocation
COEPW SEC Filings
Access official SEC EDGAR filings for Coeptis Therapeutics Holdings, Inc. (CIK: 0001759186)
📋 Recent SEC Filings
❓ Frequently Asked Questions about COEPW
What is the AI rating for COEPW?
Coeptis Therapeutics Holdings, Inc. (COEPW) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are COEPW's key strengths?
Strong current ratio of 4.16x indicates short-term liquidity to meet immediate obligations. Minimal debt burden with 0.01x debt-to-equity ratio providing financial flexibility.
What are the risks of investing in COEPW?
Extreme cash burn of $8.6M annually against only $1.4M revenue is unsustainable; ~8 months of cash runway remaining. Operating margin of -956.9% and net margin of -874.3% indicate massive losses with no near-term profitability path.
What is COEPW's revenue and growth?
Coeptis Therapeutics Holdings, Inc. reported revenue of $1.4M.
Does COEPW pay dividends?
Coeptis Therapeutics Holdings, Inc. does not currently pay dividends.
Where can I find COEPW SEC filings?
Official SEC filings for Coeptis Therapeutics Holdings, Inc. (CIK: 0001759186) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is COEPW's EPS?
Coeptis Therapeutics Holdings, Inc. has a diluted EPS of $-2.81.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.